10x Genomics (TXG) Operating Leases (2020 - 2026)

10x Genomics (TXG) has 7 years of Operating Leases data on file, last reported at $81.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 15.23% year-over-year to $81.4 million; the trailing twelve-month figure through Mar 2026 stood at $81.4 million (up 15.23% YoY), and the FY2025 full-year result was $73.4 million, changed 0.07% from the prior year.
• Operating Leases advanced to $81.4 million in Q1 2026, from $73.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $102.0 million in Q1 2023 to a low of $70.6 million in Q1 2025.
• A 5-year average of $87.5 million and a median of $87.0 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases jumped 52.5% in 2022 and retreated 23.37% in 2025, its largest moves.
• Tracing TXG's Operating Leases over 5 years: stood at $86.1 million in 2022, then decreased by 2.66% to $83.8 million in 2023, then fell by 12.55% to $73.3 million in 2024, then climbed by 0.07% to $73.4 million in 2025, then advanced by 10.92% to $81.4 million in 2026.
• Business Quant data shows TXG's Operating Leases at $81.4 million in Q1 2026, $73.4 million in Q4 2025, and $87.0 million in Q3 2025.